Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...
3d
Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...
Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Erbitux (cetuximab) is a prescription drug that’s used to treat certain types of cancer. The drug comes as a solution that’s given through a vein by a healthcare professional. It’s usually ...
Cetuximab (Erbitux) is a chimeric monoclonal IgG1 antibody produced in a mammalian cell line (Sp2/0) by recombinant DNA technology, acts as anti-neoplastic agent. It is formulated as injection, ...
5-FU: 5-Fluorouracil; ECOG: Eastern Cooperative Oncology Group; EXTREME: Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer; LA: Locoregionally advanced; LC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback